艾滋病抗病毒治疗患者焦虑、抑郁及睡眠障碍发生情况及影响因素分析  

Analysis on the Occurrence and Influencing Factors of Anxiety,Depression and Sleep Disorders in HIV/AIDS Patients Treated with Antiviral Therapy

作　　者：曾点点 金永梅 田波 李重熙 刘俊 Zeng Diandian;Jin Yongmei;Tian Bo;Li Chongxi;Liu Jun(College of Public Health,Dali University,Dali,Yunnan 671000,China;No.1 Department of Infection,Kunming Third People's Hospital,Kunming 650000,China)

机构地区：[1]大理大学公共卫生学院,云南大理671000 [2]昆明市第三人民医院感染一科,昆明650000

出　　处：《大理大学学报》2023年第4期86-91,共6页Journal of Dali University

基　　金：云南省教育厅科学研究基金项目(2020J0610)。

摘　　要：目的:研究分析艾滋病抗病毒治疗患者焦虑、抑郁及睡眠障碍发生情况及影响因素。方法:对2021年12月至2022年3月在昆明市第三人民医院就医的1200例HIV/AIDS患者进行问卷调查,问卷采用医院焦虑、抑郁情绪测量表和匹兹堡睡眠指数量表,调查接受不同抗病毒治疗方案HIV/AIDS患者焦虑、抑郁及睡眠障碍情况,应用单因素分析和多因素Logistic回归分析明确患者焦虑、抑郁及睡眠障碍的影响因素。结果:1200例HIV/AIDS患者焦虑、抑郁、睡眠障碍发生率分别为24.9%、30.7%、39.2%,同时发生焦虑、抑郁、睡眠障碍11.0%,同时合并焦虑、抑郁20.6%。多因素Logistic回归分析结果显示,男性、有稳定工作、治疗时间在3个月以下为焦虑的保护因素,接受依非韦伦治疗方案为焦虑的危险因素;男性、有稳定工作为抑郁的保护因素,接受含非核苷类逆转录酶抑制剂和蛋白酶抑制剂治疗方案为抑郁的危险因素;有稳定工作为睡眠障碍的保护因素,接受含非核苷类逆转录酶抑制剂和蛋白酶抑制剂治疗方案为睡眠障碍的危险因素。结论:HIV/AIDS患者发生焦虑、抑郁及睡眠障碍受抗病毒治疗影响较大,整合酶抑制剂神经精神毒副反应发生率低于非核苷类逆转录酶抑制剂及蛋白酶抑制剂,应加强对患者精神状况的监测,根据患者情况优化方案。Objective:To analyze the occurrence of anxiety,depression and sleep disorders in HIV/AIDS patients treated with antiretroviral therapy and analyze the influencing factors.Methods:Questionnaires were administered to 1200 HIV/AIDS patients attending Kunming Third People's Hospital from Decembor 2021 to March 2022.The questionnaires used the Hospital Anxiety and Depression Scale and the Pittsburgh Sleep Quality Index to investigate anxiety,depression and sleep disorders in HIV/AIDS patients receiving different antiretroviral treatment regimens.Univariate analysis and multifactorial Logistic regression analysis were used to analyze the factors influencing patients'anxiety,depression and sleep disorders.Results:The prevalence of anxiety,depression,and sleep disorders in 1200 HIV/AIDS patients was 24.9%,30.7%,and 39.2%,respectively,and 11.0%had concurrent anxiety,depression,and sleep disorders,and 20.6%had combined anxiety and depression.The results of multifactorial Logistic regression analysis showed that male,having a stable job,treatment time less than 3 months were the protective factors of anxiety,and receiving efavirenz treatment was a risk factor of anxiety;male and having a stable job were the protective factors of depression,and receiving treatment regimens containing non-nucleoside reverse transcriptase inhibitors and protease inhibitors were the risk factors of depression;having a stable job was a protective factor of sleep disorders,and receiving treatment regimens containing non-nucleoside reverse transcriptase inhibitors and protease inhibitors were the risk factors of sleep disorders.Conclusion:The incidence of anxiety,depression and sleep disorders in HIV/AIDS patients is more seriously affected by antiretroviral therapy.The incidence of neuropsychotoxic side effects of integrase inhibitors is lower than that of non-nucleoside reverse transcriptase inhibitors and protease inhibitors,and the monitoring of patients'mental status should be strengthened to optimize the protocol according to patients'condit

关 键 词：抗逆转录病毒药 艾滋病 焦虑 抑郁 睡眠障碍 

分 类 号：R512.91[医药卫生—内科学]